Oral calcimimetics on secondary hyperparathyroidism of uremia
Imanishi, Y.
Clinical Calcium 27(4): 561-566
2017
ISSN/ISBN: 0917-5857 PMID: 28336833 Document Number: 17203
Secondary hyperparathyroidism of uremia is associated with poor health outcomes, including all-cause mortality, cardiovascular mortality, and fractures. Standard therapy for secondary hyperparathyroidism includes vitamin D receptor activators, and phosphate binders. Persistently elevated parathyroid hormone(PTH)levels may require the addition of calcimimetics which sensitizes calcium-sensing receptors on the parathyroid glands.
Document emailed within 1 workday
